WuXi Biologics Makes Its Mark in Sustainability
WuXi Biologics, a prominent player in the global Contract Research, Development, and Manufacturing Organization (CRDMO) space, has earned a spot in the 2025 S&P Global Sustainability Yearbook. This recognition is a testament to the company’s unwavering commitment to sustainability, marking the third consecutive year that WuXi Bio has achieved this honor.
A Recognition of Excellence
In 2024, WuXi Biologics achieved an impressive top 1% rating in the S&P Global Corporate Sustainability Assessment (CSA). This prestigious acknowledgment places WuXi Bio at the forefront of sustainability practices within its industry. Out of a vast pool of 7,690 assessed companies, only 780 met the high standards required to be included in the Yearbook, highlighting WuXi Bio’s exceptional performance.
Dr. Chris Chen, the CEO of WuXi Biologics and Chairman of its ESG Committee, expressed pride in the achievement. He stated, “Being selected for the Yearbook again reflects our ongoing commitment to improving our sustainability performance. As a leader in Green CRDMO, we strive for ESG excellence and collaborate with our partners around the globe to uphold responsible practices across the value chain.”
Sustained Commitment to Sustainability
WuXi Biologics has not only made strides in the past year but has also been recognized in the Dow Jones Sustainability Indices (DJSI) for both 2023 and 2024. This comes as the company actively participates in various sustainability initiatives, including the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). The accolades earned by WuXi Biologics, including an MSCI AAA Rating, EcoVadis Platinum Medal, and a spot on the CDP Water Security “A List,” underscore their leadership in promoting sustainable business practices.
Moreover, WuXi Biologics is noted for its contributions to the UNGC’s collection celebrating 20 years of sustainable development. The company has also been recognized as a top-rated firm in the Sustainalytics industry and regional ESG categories for five years running, showcasing a consistent commitment to sustainability and environmental stewardship.
A Holistic Approach to ESG
Emphasizing the importance of Environmental, Social, and Governance (ESG) responsibilities, WuXi Biologics integrates these values into its core business strategy. The company employs advanced biomanufacturing technologies and clean energy resources in its operations. Their dedicated ESG committee, led by Dr. Chen, ensures the execution of comprehensive sustainability strategies, further cementing the company's role as an industry leader in responsible practices.
With over 12,000 skilled employees located around the globe, including in China, the United States, Ireland, Germany, and Singapore, WuXi Biologics continues to support numerous integrated client projects. As of the end of December 2024, they were involved in 817 distinct projects, leveraging their expertise to deliver effective solutions in the field of biologics.
In conclusion, WuXi Biologics has firmly established itself as a trailblazer in the realm of corporate sustainability. Recognized for their achievements and continued efforts in fostering responsible practices, they set a benchmark for CRDMOs worldwide. WuXi's commitment to advancing sustainability not only benefits the company but also contributes significantly to the health and well-being of communities globally.
For more in-depth information about WuXi Biologics and their sustainability initiatives, visit
WuXi Biologics.